dr. mirza on the impact of parp inhibitors in ovarian cancer
Published 6 years ago • 56 plays • Length 0:53Download video MP4
Download video MP3
Similar videos
-
8:29
esmo 2019: dr. mirza on important trials with parp inhibitors in ovarian cancer
-
2:18
dr. mirza on efficacy of niraparib/bevacizumab combo in recurrent ovarian cancer
-
0:57
dr. mirza on impact of niraparib in ovarian cancer
-
1:30
dr. mirza on niraparib efficacy across ovarian cancer subgroups
-
1:11
dr. berek discusses the impact of parp inhibitors on ovarian cancer
-
6:20
parp inhibitors in recurrent ovarian cancer
-
1:35
dr. mirza on the phase iii nova trial in ovarian cancer
-
1:30
dr. mirza on the evolving treatment landscape in recurrent ovarian cancer
-
1:41
dr. mirza on niraparib plus bevacizumab combo in ovarian cancer
-
0:52
dr. mirza on safety profile of niraparib/bevacizumab in recurrent ovarian cancer
-
3:44
the future role of parp inhibition in ovarian cancer
-
59:14
parp inhibitors in ovarian cancer: clinical updates from sgo 2023
-
5:53
adverse-effect profiles of parp inhibitors in ovarian cancer
-
5:34
differences among parp inhibitors in ovarian cancer
-
1:22
dr. gunderson on the use of parp inhibitors in all-comers with ovarian cancer
-
2:22
dr. konecny on the value of parp inhibitors in ovarian cancer
-
1:25
dr. emens on the combination of checkpoint inhibitors and parp inhibitors in ovarian cancer
-
6:35
parp inhibitor side effect management in ovarian cancer
-
0:27
parp inhibitors #short